title: Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril.
abstract: This study assessed the usefulness of the oral captopril test in the prediction of renal impairment among elderly patients with congestive heart failure (CHF). Forty-seven patients aged > or = 65 years with CHF (EF < 40%) participated in a prospective nonrandomized series. Blood samples for plasma renin activity (PRA) were drawn before and 60 minutes after 50 mg of oral captopril. Twenty-four hours later, captopril was administered (up to 75 mg/day over a 4 day period), and renal laboratory and clinical assessment were performed at baseline and for a 9 day period. In 7 of 47 patients (14.9%), deterioration of renal function was observed. During the captopril test, the PRA increased significantly after 1 hour in almost all patients and the mean blood pressure decreased from 99.2 +/- 14.6 mmHg to 92.2 +/- 13.7 mmHg (p < 0.001). All patients whose baseline PRA level was < 1.9 ng/ml/hr and whose stimulated PRA was < 3.2 ng/ml/hr maintained a stable renal function throughout the study period. Significant statistical correlation (p < 0.05) was found between the initial PRA, the changes in PRA or mean blood pressure during the captopril test, and the change in plasma creatinine and creatinine clearance in the entire group, and was even more evident in a subgroup of patients with an ejection fraction > or = 30%. All these correlations were not statistically significant in the patients with an ejection fraction < 30%. It is thus concluded that measurement of pretreatment PRA levels might be a useful laboratory tool for predicting the renal safety of captopril use in patients with CHF whose EF > or = 30%.
authors.affiliation: Department of Internal Medicine T, Ichilov Hospital, Tel-Aviv Sourasky Medical Center, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Schwartz
authors.forename: R
authors.initials: R
authors.lastname: Kornowski
authors.forename: I F
authors.initials: IF
authors.lastname: Schwartz
authors.forename: I
authors.initials: I
authors.lastname: Dotan
authors.forename: B
authors.initials: B
authors.lastname: Weinreb
authors.forename: M
authors.initials: M
authors.lastname: Averbuch
authors.forename: Y
authors.initials: Y
authors.lastname: Golan
authors.forename: Y
authors.initials: Y
authors.lastname: Levo
authors.forename: A
authors.initials: A
authors.lastname: Iaina
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012083:Renin / Q000097:blood*; D012449:Safety
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D003404:Creatinine; D012083:Renin